Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer

Joo H. Sohn, Hei C. Jeung, Hyun J. Shin, SunYoung Rha, Jae K. Roh, Sung H. Noh, Jin S. Min, Byung S. Kim, Woo I. Jang, Hyuncheol Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We evaluated the efficacy and tolerability of a combination chemotherapy including infusional fluorouracil (5-FU), etoposide, and cisplatin (FEP) in 89 patients with advanced/relapsed gastric cancer. Primary endpoints were progression-free and overall survival. Secondary endpoints were response rates, response duration, and toxicity. The treatment schedule was as follows: 5-FU 1,000 mg/m2 and etoposide 100 mg/m2 were administered on 3 consecutive days and cisplatin at 80 mg/m2 was administered on day 2, and repeated every 3 weeks. The median times to progression and overall survival were 4 and 8 months, respectively. One-year progression-free and overall survival rates were 10% and 33%, respectively. The overall response rate for 25 eligible patients with measurable disease was 20% (5/25, complete response 2, partial response 3) with median response duration of 7 months. Median actual dose intensities of 5-FU, etoposide, and cisplatin were 700 mg/m2/ wk, 70 mg/m2/wk, and 21 mg/m2/wk, respectively. Median relative dose intensities of 5-FU, etoposide, and cisplatin were 0.70, 0.70, and 0.63, respectively. In conclusion, the FEP regimen was found to produce therapeutic results similar to those of other combination chemotherapeutic studies and to have an acceptable toxicity. This regimen could be used as one of the options for advanced gastric cancer chemotherapy in patients unsuitable for doxorubicin-based regimens.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number2
DOIs
Publication statusPublished - 2003 Apr 1

Fingerprint

Etoposide
Fluorouracil
Cisplatin
Stomach Neoplasms
Disease-Free Survival
Combination Drug Therapy
Doxorubicin
Appointments and Schedules
Survival Rate
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sohn, Joo H. ; Jeung, Hei C. ; Shin, Hyun J. ; Rha, SunYoung ; Roh, Jae K. ; Noh, Sung H. ; Min, Jin S. ; Kim, Byung S. ; Jang, Woo I. ; Chung, Hyuncheol. / Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 2. pp. 203-209.
@article{b392eb29251d4498b594e293c14a0ee6,
title = "Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer",
abstract = "We evaluated the efficacy and tolerability of a combination chemotherapy including infusional fluorouracil (5-FU), etoposide, and cisplatin (FEP) in 89 patients with advanced/relapsed gastric cancer. Primary endpoints were progression-free and overall survival. Secondary endpoints were response rates, response duration, and toxicity. The treatment schedule was as follows: 5-FU 1,000 mg/m2 and etoposide 100 mg/m2 were administered on 3 consecutive days and cisplatin at 80 mg/m2 was administered on day 2, and repeated every 3 weeks. The median times to progression and overall survival were 4 and 8 months, respectively. One-year progression-free and overall survival rates were 10{\%} and 33{\%}, respectively. The overall response rate for 25 eligible patients with measurable disease was 20{\%} (5/25, complete response 2, partial response 3) with median response duration of 7 months. Median actual dose intensities of 5-FU, etoposide, and cisplatin were 700 mg/m2/ wk, 70 mg/m2/wk, and 21 mg/m2/wk, respectively. Median relative dose intensities of 5-FU, etoposide, and cisplatin were 0.70, 0.70, and 0.63, respectively. In conclusion, the FEP regimen was found to produce therapeutic results similar to those of other combination chemotherapeutic studies and to have an acceptable toxicity. This regimen could be used as one of the options for advanced gastric cancer chemotherapy in patients unsuitable for doxorubicin-based regimens.",
author = "Sohn, {Joo H.} and Jeung, {Hei C.} and Shin, {Hyun J.} and SunYoung Rha and Roh, {Jae K.} and Noh, {Sung H.} and Min, {Jin S.} and Kim, {Byung S.} and Jang, {Woo I.} and Hyuncheol Chung",
year = "2003",
month = "4",
day = "1",
doi = "10.1097/00000421-200304000-00022",
language = "English",
volume = "26",
pages = "203--209",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer. / Sohn, Joo H.; Jeung, Hei C.; Shin, Hyun J.; Rha, SunYoung; Roh, Jae K.; Noh, Sung H.; Min, Jin S.; Kim, Byung S.; Jang, Woo I.; Chung, Hyuncheol.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 2, 01.04.2003, p. 203-209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer

AU - Sohn, Joo H.

AU - Jeung, Hei C.

AU - Shin, Hyun J.

AU - Rha, SunYoung

AU - Roh, Jae K.

AU - Noh, Sung H.

AU - Min, Jin S.

AU - Kim, Byung S.

AU - Jang, Woo I.

AU - Chung, Hyuncheol

PY - 2003/4/1

Y1 - 2003/4/1

N2 - We evaluated the efficacy and tolerability of a combination chemotherapy including infusional fluorouracil (5-FU), etoposide, and cisplatin (FEP) in 89 patients with advanced/relapsed gastric cancer. Primary endpoints were progression-free and overall survival. Secondary endpoints were response rates, response duration, and toxicity. The treatment schedule was as follows: 5-FU 1,000 mg/m2 and etoposide 100 mg/m2 were administered on 3 consecutive days and cisplatin at 80 mg/m2 was administered on day 2, and repeated every 3 weeks. The median times to progression and overall survival were 4 and 8 months, respectively. One-year progression-free and overall survival rates were 10% and 33%, respectively. The overall response rate for 25 eligible patients with measurable disease was 20% (5/25, complete response 2, partial response 3) with median response duration of 7 months. Median actual dose intensities of 5-FU, etoposide, and cisplatin were 700 mg/m2/ wk, 70 mg/m2/wk, and 21 mg/m2/wk, respectively. Median relative dose intensities of 5-FU, etoposide, and cisplatin were 0.70, 0.70, and 0.63, respectively. In conclusion, the FEP regimen was found to produce therapeutic results similar to those of other combination chemotherapeutic studies and to have an acceptable toxicity. This regimen could be used as one of the options for advanced gastric cancer chemotherapy in patients unsuitable for doxorubicin-based regimens.

AB - We evaluated the efficacy and tolerability of a combination chemotherapy including infusional fluorouracil (5-FU), etoposide, and cisplatin (FEP) in 89 patients with advanced/relapsed gastric cancer. Primary endpoints were progression-free and overall survival. Secondary endpoints were response rates, response duration, and toxicity. The treatment schedule was as follows: 5-FU 1,000 mg/m2 and etoposide 100 mg/m2 were administered on 3 consecutive days and cisplatin at 80 mg/m2 was administered on day 2, and repeated every 3 weeks. The median times to progression and overall survival were 4 and 8 months, respectively. One-year progression-free and overall survival rates were 10% and 33%, respectively. The overall response rate for 25 eligible patients with measurable disease was 20% (5/25, complete response 2, partial response 3) with median response duration of 7 months. Median actual dose intensities of 5-FU, etoposide, and cisplatin were 700 mg/m2/ wk, 70 mg/m2/wk, and 21 mg/m2/wk, respectively. Median relative dose intensities of 5-FU, etoposide, and cisplatin were 0.70, 0.70, and 0.63, respectively. In conclusion, the FEP regimen was found to produce therapeutic results similar to those of other combination chemotherapeutic studies and to have an acceptable toxicity. This regimen could be used as one of the options for advanced gastric cancer chemotherapy in patients unsuitable for doxorubicin-based regimens.

UR - http://www.scopus.com/inward/record.url?scp=0037391178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037391178&partnerID=8YFLogxK

U2 - 10.1097/00000421-200304000-00022

DO - 10.1097/00000421-200304000-00022

M3 - Article

C2 - 12714898

AN - SCOPUS:0037391178

VL - 26

SP - 203

EP - 209

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -